At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 83 enrolled
Drug / intervention
nab-paclitaxel +1 moredrug
Likely dose
nab-paclitaxel 125 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 2, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ABI-007 PLUS GEMCITABINE IN CHINESE PATEINTS WITH METASTATIC PANCREATIC ADENOCARCINOMA
In Brief
A Phase 2 clinical trial evaluating nab-paclitaxel and Gemcitabine for Pancreatic Neoplasms. Completed, enrolled 83 participants across 15 sites.
Detailed Summary
The purpose of this study is to determine the safety and efficacy of nab-paclitaxel combined with gemcitabine in Chinese patients with metastatic pancreatic cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Neoplasms
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 2013
Enrollment StartDec 2013
Primary CompletionJun 2015
Study CompletionAug 2016
TodayJul 2026
First PostedDec 20, 2013
Enrollment StartDec 24, 2013
Primary CompletionJun 1, 2015
Study CompletionAug 3, 2016
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 12.5 years ago
Interventions
nab-paclitaxeldrug
nab-paclitaxel at 125 mg/m\^2, by IV infusion over 30 to 40 minutes (maximum infusion time not to exceed 40 minutes)
Gemcitabinedrug
Gemcitabine at 1000 mg/m\^2 IV infusion over 30 to 40 minutes given once weekly for 3 weeks (Days 1, 8 and 15) followed by a week of rest (28 day cycle).